





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FI	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/599,371	(	06/22/2000	John D. Nelson	101992-200	8796
27267	7590	10/24/2002			
WIGGIN &		<del></del>	EXAMINER		
ATTENTION: PATENT DOCKETING ONE CENTURY TOWER, P.O. BOX 1832 NEW HAVEN, CT 06508-1832			32	LEVY, NEIL S	
				ART UNIT	PAPER NUMBER
				1616	
				DATE MAILED: 10/24/2002	!

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary  Application No. 5999  Examiner,	Applicant(s) Peluson Aul Group Art Unit 12
NET	Clary 1616 13
—The MAILING DATE of this communicati n appears on the cover	sheet beneath the correspondence address-
P riod for Reply	
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE OF THIS COMMUNICATION.	MONTH(S) FROM THE MAILING DATE
<ul> <li>Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no even from the mailing date of this communication.</li> <li>If the period for reply specified above is less than thirty (30) days, a reply within the statut</li> <li>If NO period for reply is specified above, such period shall, by default, expire SIX (6) MON</li> <li>Failure to reply within the set or extended period for reply will, by statute, cause the application.</li> </ul>	ory minimum of thirty (30) days will be considered timely.
Status G 4/07	
Responsive to communication(s) filed on	•
fhis action is FINAL.	
Since this application is in condition for allowance except for formal matte accordance with the practice under Ex parte Quayle, 1935 C.D. 1 1; 453 C.D. 1 1	
Disposition of Claims	
(Delaim(s) 1-3,5, 8-11, 33,34, 43-58	is/are pending in the application.
Of the above claim(s)	is/are withdrawn from consideration.
□ Claim(s)	is/are allowed.
1-358-//33,34,43-58	is/are rejected.
□ Claim(a)	is/are objected to.
$9^{\text{Claim(s)}} \frac{1-3}{5} \frac{5}{8} \frac{8-11}{1} \frac{3334}{334} \frac{43-58}{1}$	are subject to restriction or election
	requirement.
Application Papers	
Application Papers   See the attached Notice of Draftsperson's Patent Drawing Review, PTO-9	948.
☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-9	proved 🗆 disapproved.
☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-9 ☐ The proposed drawing correction, filed on is ☐ app	proved 🗆 disapproved.
☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-S☐ The proposed drawing correction, filed on is ☐ app ☐ The drawing(s) filed on is/are objected to by the Example of the proposed drawing is/are objected to be are	proved 🗆 disapproved.
<ul> <li>□ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-S</li> <li>□ The proposed drawing correction, filed on is □ app</li> <li>□ The drawing(s) filed on is/are objected to by the Examiner.</li> <li>□ The specification is objected to by the Examiner.</li> <li>□ The oath or declaration is objected to by the Examiner.</li> </ul>	proved 🗆 disapproved.
<ul> <li>□ The proposed drawing correction, filed on is □ apple □ The drawing(s) filed on is/are objected to by the Examiner.</li> <li>□ The specification is objected to by the Examiner.</li> <li>□ The oath or declaration is objected to by the Examiner.</li> <li>Pri rity under 35 U.S.C. § 119 (a)-(d)</li> <li>□ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. §</li> <li>□ All □ Some* □ None of the CERTIFIED copies of the priority document of the complex of the complex of the priority document of the complex of the priority document of the complex of the comple</li></ul>	oroved disapproved. aminer.  11 9(a)-(d). ments have been
<ul> <li>□ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-9</li> <li>□ The proposed drawing correction, filed on</li></ul>	oroved disapproved. aminer.  11 9(a)-(d). ments have been  u (PCT Rule 1 7.2(a)).
<ul> <li>□ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-S</li> <li>□ The proposed drawing correction, filed on</li></ul>	oroved disapproved. aminer.  11 9(a)-(d). ments have been  u (PCT Rule 1 7.2(a)).
□ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-9 □ The proposed drawing correction, filed on	oroved disapproved.  aminer.  11 9(a)-(d).  ments have been  U (PCT Rule 1 7.2(a)).
□ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-9 □ The proposed drawing correction, filed on	oroved disapproved.  aminer.  11 9(a)-(d).  ments have been  U (PCT Rule 1 7.2(a)).
□ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-9 □ The proposed drawing correction, filed on	oroved disapproved.  aminer.  11 9(a)-(d).  ments have been  U (PCT Rule 1 7.2(a)).

S. Patent and Trademark Office 326 (Rev. 9-97)

Part of Paper No.

Application/Control Number: 09/599,371

Art Unit: 1616

Receipt is acknowledged of Request for Time, Amendment, and IDS (9/14/02).

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 1-3, 5, 8-11, 33, 34, 43-58 are rejected under 35 U.S.C. 102(b) as being anticipated by Kappock et al 5518774.

The rejection of record is maintained. It is well known to provide the compositions as claimed, of pyrithione and heavy metal ion sources; exemplified here by Kappock, Examiner does not find the mechanism of action for the instant claimed composition identified by Kappock, nor even concern for efficacy in the aqueous environment, but the instant invention as claimed is a composition, and Kappock shows it, antimicrobially effective, in aqueous environments (column 3), at a 10:1 to 1:10 level. Note that organic solvents are not required.

Claims 1-3, 3, 5, 8, 11, 33, 34 and 43-58 are rejected under 35 U.S.C. 102(b) as being anticipated by Wiese-5227156.

A pyrithione complex, zinc, pyrithione (column 3) is prepared with zinc oxide hydroxides or salts, in aqueous composition, at 10 to 1 ratio.

Claims 1-3, 8, 11, 44, 47, 48, 53, 54, 57 and 58 are rejected under 35 U.S.C. 102(b) as being anticipated by Dixon et al EP 077630.

ZPT with chelating agent and copper ions is antimicrobially enhanced (page 2) EDTA (page 3, paragraph 2) is the chelating agent; copper salts, the ion source (page 4, last paragraph) at the instant ratio's (page 4, paragraphs 1, 3). **4** 

Application/Control Number: 09/599,371

Art Unit: 1616

Claims 1-3, 5, 8, 11, 33, 34, 43-46, 51 and 58 are rejected under 35

U.S.C. 102(b) as being anticipated by Khattar et al `93.

See page 175, 176.

Applicant's arguments filed 7/5/02 have been fully considered but they are not persuasive. Applicant's arguments are not persuasive; they are addressed above—the prior art provides the composition ad are instantly claimed; the particular functions thereof are not given patentable weight.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Neil Levy whose telephone number is 308-2412. The examiner can normally be reached on Tuesday- Friday 7:00 am to 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jose Dees can be reached on 308-4628. The fax phone numbers for the organization where this application or proceeding is assigned are 30\$\mathbb{E}\$-4556 for regular communications and 305-3592 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 308-1235.

Levy: mv

October 21, 2002

NEIL S. LEVY
PRIMARY EXAMINER

Melley